期刊文献+

黏膜性类天疱疮68例临床回顾分析 被引量:3

Mucous membrane pemphigoid: a retrospective study of 68 cases
原文传递
导出
摘要 目的总结1987年8月至2012年10月我科诊治的68例黏膜性类天疱疮的临床特点和治疗经验。方法总结黏膜性类天疱疮患者黏膜皮肤损害、组织病理改变、免疫学等方面的特点,重点分析治疗方案。结果黏膜性类天疱疮68例,累及口腔黏膜67例占98.5%,眼部黏膜23例占33.8%。免疫学检查:16例行直接免疫荧光检查(DIF),8例阳性;39例行间接免疫荧光检查(IIF),8例阳性,阳性率20.5%;41例采用ELISA法检测血清中抗BP180抗体,22例阳性,阳性率53.7%。依据皮损分布确定病情严重程度后,予以局部治疗5例;中低剂量糖皮质激素系统治疗(0.4—0.5mg·kg^-1·d^-1,或30mg/d)55例,其中3例同时累及皮肤、口腔黏膜、眼结膜及其他黏膜的患者剂量增加至50mg/d左右才能控制病情。控制剂量起效时间(11.80±5.88)d,控制剂量服药时间0.23~12(3.06±2.84)个月。15例患者基本治愈,其中4例完全治愈。基本治愈患者糖皮质激素剂量减至原剂量50%所需时间为(13.29±5.76)个月,达到基本治愈所需时间为(17.33±7.71)个月。病情控制6个月后,剂量平均减至控制剂量的76.5%,12个月后剂量平均减至控制剂量的58.1%。3例患者在治疗过程中出现口腔念珠菌感染。结论黏膜性类天疱疮的诊断目前主要依据典型的临床和病理表现,尚缺乏灵敏度高的免疫学检查手段。中低剂量糖皮质激素系统治疗,配合局部治疗,常可达满意疗效。 Objective To analyze the clinical features and treatment of 68 cases of mucous membrane pemphigoid (MMP). Methods Clinical data were collected from 68 patients with MMP at the Department of Dermatology, Peking University First Hospital, between August 1987 and October 2012. Skin manifestations, histopathological and immunological findings were studied, with an emphasis on treatment regimens. Results The two most frequently involved sites were oral (67/68, 98.5%) and conjunctival (23/68, 33.8%) mucosa in patients with MMP. Immunological examinations included direct immunofluorescence test, indirect immunofluorescence test and enzyme-linked immunosorbent assay, with a positivity rate of 50% (8/16), 20.5% (8/39) and 53.7% (22/41) respectively. According to lesion distribution and disease severity, patients were given local therapy (n = 5) or low to moderate dose of glucocorticoids (n = 55, 0.4 - 0.5 mg/kg or 30 mg per day). The condition was controlled until the dose of glucocorticoids reached 50 mg/d in three patients with cutaneous, oral, ocular, and other mucosal involvement. The time to onset of action of glucocorticoids at the controlling dose was ( 11.80 ± 5.88) days, and the duration of administration of glucoeorticoids at this dose varied from 0.23 to 12 months (average, 3.06 ± 2.84 months). Fifteen patients were almost cured, and four patients completely cured. Of the 15 patients almost cured, the time required for a 50% reduction in the dose of glueocortieoids was (13.29 ± 5.76) months,and that required for the control of MMP was (17.33 ± 7.71 ) months. The dose of glucocortieoids was decreased to 76.5% of the controling dose at 6 months after the control of MMP, and 58.1% of that at 12 months. Oral candidiasis occurred in three patients during the treatment. Conclusions The diagnosis of MMP is mainly based on typical clinical and histopathological findings, and current immunological examinations are insufficiently sensitive. Usually, low to moderate dose of systemic corticosteroids combined with topical therapy can lead to satisfactory treatment outcomes.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2013年第11期788-791,共4页 Chinese Journal of Dermatology
基金 国家自然科学基金青年科学基金(81000694) 北京大学-清华大学生命科学联合中心临床青年优秀人才科研课题(201309)
关键词 类天疱疮 良性黏膜 回顾性研究 药物疗法 Pemphigoid, benign mucous membrane Retrospective studies Drug therapy
  • 相关文献

参考文献18

  • 1Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol, 1995, 131( 1 ): 48-52.
  • 2Chan LS. Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid). Clin Dermatol, 2012, 30( 1 ): 34-37.
  • 3Calabresi V, Carrozzo M, Cozzani E, et al. Oral pemphigoid autoantibodies preferentially target BP180 ectodomain. Clin Immunol, 2007, 122(2): 207-213.
  • 4Hayashi I, Shinkuma S, Shimizu S, et al. Mucous membrane pemphigoid with generalized blisters: IgA and IgG autoantibodies target both laminin-332 and type XVII collagen. Br J Dermatol, 2012, 166(5): 1116-1120.
  • 5Tseng SC, Di Pascuale MA, Liu DT, et al. Intranperative mimmycin C and amniotic membrane transplantation for fomix reconstruction in severe cieatricial ocular surface diseases. Ophthalmology, 2005, 112(5): 896-903.
  • 6Knudson RM, Kalaaji AN, Bruce AJ. The management of mucous membrane pemphigoid and pemphigus. Dermatol Ther, 2010, 23 (3): 268-280.
  • 7Kasperkiewicz M, Shimanovich I, Ludwig J, et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol, 2011, 65(3 ): 552-558.
  • 8Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cieatricial pemphigoid: a preliminary report. Ophthalmology, 2010, 117 ( 5 ): 861-869.
  • 9Schumann T, Schmidt E, Booken N, et al. Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab. Acta Derm Venereol, 2009, 89( 1 ): 101-102.
  • 10Ross AH, Jaycock P, Cook SD, et al. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br J Ophthalmol, 2009, 93(4): 421-422.

同被引文献16

  • 1Pohla-Gubo G, Hintner H. Direct and indirect immunofluores- cence for the diagnosis of bullous autoimmune diseases [J]. Der- matol Clin, 2011,29(3): 365-372.
  • 2Suliman NM, Astrom AN, Ali RW, et al. Clinical and histologi- cal characterization of oral pemphigus lesions in patients with skin diseases: a cross-sectional study from Sudan [J]. BMC Oral Health, 2013, 13(1): 66.
  • 3Arundhathi S, Ragunatha S, Mahadeva KC. A cross-sectional study of clinical, histopathological and direct immunofluores- cence spectrum of vesiculobullous disorders [J]. J Clin Diagn Res, 2013, 7(12): 2788-2792.
  • 4Baum S, Sakka N, Artsi O, et al. Diagnosis and classification of autoimmune blistering diseases [J]. Autoimmun Rev, 2014, 13 (4) : 482-489.
  • 5Kanwar AJ, De D. Pemphigus in India [J]. Indian J Dermatol V enereol Leprol, 2011,77 (4) : 439-449.
  • 6Inchara YK, Rajalakshmi T. Direct immunofluorescencc in cuta- neous vesiculobullous lesions [J]. Indian J Pathol Microbiol, 2007, 50(4): 730-732.
  • 7Sitmu C, Mihai S, Zillikens D. The relevance of the IgG subclass of autoantibodies for blister induction in autoimmunc bullous skin diseases [ J ]. Arch Dermatol Res, 2007,299 ( 1 ) : 1-8.
  • 8Hayashi I, Shinkuma S, Shimizu S, et al. Mucous membrane pemphigoid with generalized blisters: IgA and IgG autoantibod- ies target both laminin-332 and type ⅩⅦ collagen [J]. Br J Der- matol, 2012, 166(5): 1116-1120.
  • 9Cozzani E, Drosera M, Parodi A, et al. Frequency of IgA anti- bodies in pemphigus, bullous pemphigoid and mucous mem- brane pemphigoid [J]. Acta Derm Venereol, 2004, 84 (5) : 381-384.
  • 10Helander SD, Rogers RS 3rd .The sensitivity and specificity of direct immunofluoreseene testing in disorders of mucous mem- branes[J]. J Am Dermatol, 1994, 30( 1 ) :65-75 .

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部